Taysha Gene Therapies Inc (TSHA) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $4.57
• Market Cap: $1.28B
• EPS: $-0.33
• 52-Week High: $6.02
• 52-Week Low: $1.05

Market Sentiment

Taysha Gene Therapies Inc currently has a Neutral sentiment score of 0.04.

About Taysha Gene Therapies Inc

Taysha Gene Therapies, Inc. is a leading gene therapy company based in Dallas, Texas, specializing in the development and commercialization of adeno-associated virus-based therapies aimed at treating monogenic diseases affecting the central nervous system. With a robust pipeline of innovative therapeutics, Taysha is committed to addressing unmet medical needs in the neurology space, leveraging its proprietary gene delivery platform to advance potentially transformative treatment options. The ...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Taysha Gene Therapies Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does TSHA pay dividends?

Taysha Gene Therapies Inc (TSHA) does not currently pay a regular dividend.

What is TSHA's market cap?

Taysha Gene Therapies Inc (TSHA) has a market capitalization of $1.28B with a current stock price of $4.57.